Economic evaluation of the routine use of echocardiography versus natriuretic peptide and ECG-targeted echocardiography in the diagnosis of heart failure
Objectives: To investigate the most efficient use of echocardiography and natriuretic peptide testing in the diagnosis of heart failure.\ud \ud Design: An economic model comparing two strategies: (A) provide echocardiography and electrocardiogram (ECG) for all individuals who present to a GP with symptoms that may be due to heart failure; (B) carry out B-type natriuretic peptide (BNP) blood test and ECG on all such individuals and provide echocardiography only where an abnormality is detected in one of more of these tests.\ud \ud Setting: Primary care in the UK NHS.\ud \ud Subjects: Individuals who present to a GP with new symptoms of heart failure.\ud \ud Main outcome measures: Cost per life year gained.\ud \ud Results: Baseline cost per life year gained by strategy A compared with strategy B is £3,987.\ud \ud Conclusions: Immediate echocardiography is the most cost-effective option. Where echocardiography is a scarce resource, efficient use can be obtained by using BNP and ECG tests to identify patients most likely to have heart failure.
16 references, page 1 of 2
views in local repository
downloads in local repository
The information is available from the following content providers: